Hollow iron oxide nanoparticles as multidrug resistant drug delivery and imaging vehicles

Nano Research

Volumn 6, Issue 1, 2013, Pages 1-9

  Xing, Ruijun ^a,b   Bhirde, Ashwinkumar A ^a   Wang, Shouju ^a   Sun, Xiaolian ^a   Liu, Gang ^c   Hou, Yanglong ^a   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b PEKING UNIVERSITY   (China)

^c XIAMEN UNIVERSITY   (China)

Author keywords

doxorubicin; drug delivery; drug resistance; hollow nanoparticles; imaging (MRI); magnetic resonance

Indexed keywords

EID: 84872490925     PISSN: 19980124     EISSN: 19980000     Source Type: Journal    
DOI: 10.1007/s12274-012-0275-5     Document Type: Article

References (35)

1. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
2. Kirkin, V.; Joos, S.; Zörnig, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta-Mol. Cell Res. 2004, 1644, 229-249.
3. Kruh, G. D. Introduction to resistance to anticancer agents. Oncogene2003, 22, 7262-7264.
4. Calderwood, S. K.; Khaleque, M. A.; Sawyer, D. B.; Ciocca, D. R. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem. Sci. 2006, 31, 164-172.
5. Duhem, C.; Ries, F.; Dicato, M. What Does Multidrug resistance (MDR) expression mean in the clinic. Oncologist1996, 1, 151-158.
6. Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000, 11, 265-283.
7. Ferry, D. R.; Traunecker, H.; Kerr, D. J. Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer1996, 32A, 1070-1081.
8. Rowinsky, E. K.; Smith, L.; Wang, Y. M.; Chaturvedi, P.; Villalona, M.; Campbell, E.; Aylesworth, C.; Eckhardt, S. G.; Hammond, L.; Kraynak, M. et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J. Clin. Oncol. 1998, 16, 2964-2976.
9. Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S.; Amiji, M. M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 2008, 34, 592-602.
10. Moore, A.; Basilion, J. P.; Chiocca, E. A.; Weissleder, R. Measuring transferrin receptor gene expression by NMR imaging. Biochim. Biophys. Acta-Mol. Cell Res. 1998, 1402, 239-249.
11. Zhang, Y.; Kohler, N.; Zhang, M. Q.; Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials2002, 23, 1553-1561.
12. Ibarz, G.; Dähne, L.; Donath, E.; Möhwald, H. Smart micro- and nanocontainers for storage, transport, and release. Adv. Mater. 2001, 13, 1324-1327.
13. Zhu, H. G.; McShane, M. J. Loading of hydrophobic materials into polymer particles: Implications for fluorescent nanosensors and drug delivery. J. Am. Chem. Soc. 2005, 127, 13448-13449.
14. Sukhorukov, G. B.; Antipov, A. A.; Voigt, A.; Donath, E.; Mohwald, H. pH-controlled macromolecule encapsulation in and release from polyelectrolyte multilayer nanocapsules. Macromol. Rapid Comm. 2001, 22, 44-46.
15. Mamot, C.; Drummond, D. C.; Hong, K.; Kirpotin, D. B.; Park, J. W. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist. Update2003, 6, 271-279.
16. Forssen, E. A.; Coulter, D. M.; Proffitt, R. T. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res. 1992, 52, 3255-3261.
17. Meng, H.; Liong, M.; Xia, T.; Li, Z. X.; Ji, Z. X.; Zink, J. I.; Nel, A. E. Engineered design of mesoporous silica nano-particles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano2010, 4, 4539-4550.
18. You, J.; Zhang, G. D., Li, C. Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release. ACS Nano2010, 4, 1033-1041.
19. Xiao, Y. L.; Hong, H.; Matson, V. Z.; Javadi, A.; Xu, W. J.; Yang, Y. N,; Zhang, Y.; Engle, J. W.; Nickles, R. J.; Cai, W. B. et al. Gold nanorods conjugated with doxorubicin and cRGD for combined anticancer drug delivery and PET imaging. Theranostics, 2012, 2, 757-768.
20. Ho, D. N.; Kohler, N.; Sigdel, A.; Kalluri, R.; Morgan, J. R.; Xu, C. J.; Sun, S. H. Penetration of endothelial cell coated multicellular tumor spheroids by iron oxide nanoparticles. Theranostics2012, 2, 66-75.
21. Huang, J.; Zhong, X. D.; Wang, L. Y.; Yang, L. L.; Mao, H. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics2012, 2, 86-102.
22. Yu, M. K.; Park, J.; Jon, S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics2012, 2, 3-44.
23. Xie, J.; Chen, K.; Huang, J.; Lee, S.; Wang, J. H.; Gao, J. H.; Li, X. G.; Chen, X. Y. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials2010, 31, 3016-3022.
24. Quan, Q. M.; Xie, J.; Gao, H. K.; Yang, M.; Zhang, F.; Liu, G.; Lin, X.; Wang, A.; Eden, H. S.; Lee, S. et al. HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy. Mol. Pharmaceut. 2011, 8, 1669-1676.
25. Gao, J. H.; Liang, G. L.; Cheung, J. S.; Pan, Y.; Kuang, Y.; Zhao, F.; Zhang, B.; Zhang, X. X.; Wu, E. X.; Xu, B. Multifunctional yolk-shell nanoparticles: A potential MRI contrast and anticancer agent. J. Am. Chem. Soc. 2008, 130, 11828-11833.
26. Xu, C. J.; Xu, K. M.; Gu, H. W.; Zheng, R. K.; Liu, H.; Zhang, X. X.; Guo, Z. H.; Xu, B. Dopamine as a robust anchor to immobilize functional molecules on the iron oxide shell of magnetic nanoparticles. J. Am. Chem. Soc. 2004, 126, 9938-9939.
27. 4 nanoparticles. Angew. Chem. Int. Ed. 2007, 46, 4155-4158.
28. 4 nanoparticles for targeted delivery and controlled release of cisplatin. J. Am. Chem. Soc. 2009, 131, 10637-10644.
29. Abbasi, S.; Paul, A.; Shao, W.; Prakash, S. Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: Preparation and in vitro assessment. J. Drug Deliv., in press, DIO: 10. 1155/2012/686108.
30. Bareford, L. M.; Swaan, P. W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliver. Rev. 2007, 59, 748-758.
31. Tong, R.; Cheng, J. J. Anticancer polymeric nanomedicines. Polym. Rev. 2007, 47, 345-381.
32. Bhirde, A. A.; Kapoor, A.; Liu, G.; Iglesias-Bartolome, R.; Jin, A.; Zhang, G. F.; Xing, R. J.; Lee, S.; Leapman, R. D.; Gutkind, J. S. et al. Nuclear mapping of nanodrug delivery systems in dynamic cellular environments. ACS Nano2012, 6, 4966-4972.
33. Xiong, X. B.; Ma, Z. S.; Lai, R., Lavasanifar, A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials2010, 31, 757-768.
34. Kievit, F. M.; Wang, F. Y.; Fang, C.; Mok, H.; Wang, K.; Silber, J. R.; Ellenbogen, R. G.; Zhang, M. Q. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J. Control Release2011, 152, 76-83.
35. Huang, J.; Bu, L. H.; Xie, J.; Chen, K.; Cheng, Z.; Li, X. G.; Chen, X. Y. Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano2010, 4, 7151-7160.